Immune monitoring in pancreatic cancer

Recruiting

• Conditions: pancreatic ductal adenocarcinoma; pancreatic cancer; 10017991

• Registration Number: NL-OMON45549
• Lead Sponsor: Stichting Leveronderzoek

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 400

Inclusion Criteria

• Age >= 18 years
• Diagnosed with resectable or borderline resectable pancreatic cancer, locally
advanced pancreatic cancer or metastasized pancreatic cancer
• Planned treatment with either currently available standard of care treatments
for pancreatic cancer (e.g. surgery, gemcitabine, neoadjuvant
chemoradiotherapy, FOLFIRINOX and/or (stereotactic) radiotherapy) or new
treatment options such as, but not limited to, Ampligen® (immunotherapy) or DC
therapy.
• Signed informed consent

Exclusion Criteria

• Unable to draw blood for study purposes
• Serious concomitant systemic disorders that would compromise the safety of
the patient or his/her ability to complete the study, at the discretion of the
investigator.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>• To determine the baseline immune signature in pancreatic cancer patients. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>• To investigate whether the immune profile found in the PB reflects the local<br /><br>immune signature of the pancreatic tumor.<br /><br>• To monitor the effect of treatment (neoadjuvant CRTx, adjuvant chemotherapy<br /><br>or palliative chemotherapy) on the expression of co-inhibitory molecules and<br /><br>their ligands on TIL and PB lymphocytes.</p><br>